Good morning, Marco. The biggest thing overnight is on your Cuba beat, and it's the first
version of this policy that reaches across the water and touches people at a US airport
desk rather than only entities in Havana. On the clinical side: a PrEP result that quietly
changes what a medication list has to ask about, and an Ebola outbreak whose case-fatality
rate has more than doubled since June — with a strain our licensed countermeasures don't
cover. Debate today is cardiology's post-ZEUS reckoning. Tropics still empty. Mets were off.
Section A — Top Stories
Confirmed fresh, last 48 hours.
Cuba · Treasury & State, Aug 20
New Cuba sanctions hit ICAP's leadership — and enforcement moves to US ports of entry
Treasury and State announced sanctions Thursday on ten state-owned mining, metals and
construction companies plus the leadership of ICAP, the Cuban Institute of Friendship with
the Peoples — its president Fernando González Llort (one of the five Cuban intelligence
officers arrested in the US in 1998 and released in 2014), first vice president Noemí
Ramona Rabaza Fernández, and North America director Leima Martínez Freire. Secretary of
State Marco Rubio said ICAP sponsors a "subversive network" to "cultivate" Americans,
pointing at educational and cultural exchanges built around the 100th anniversary of Fidel
Castro's birth earlier this month. The part that's genuinely new: US authorities were
prepared to pull dozens of returning American participants into secondary screening on
arrival, and some had phones and other personal electronics seized for inspection. Far
fewer were ultimately held than the government had staged for.
(WLRN ·
ABC News / AP ·
Washington Times)
Why it matters to you: every previous round this year — the Rubio
designations on the 17th, the entity listings before that — landed on Cuban institutions.
This one lands on Americans, at the jetway. For a Florida household with family who still
travel, the operative change isn't the sanctions list; it's that a lawful return trip can
now end in a device seizure. Also worth noting what this does to the medical-exchange and
humanitarian-delegation traffic that runs through ICAP.
Talking point: if anyone in your circle has a Cuba trip booked, the
practical advice is boring and useful — travel with a clean phone, keep the OFAC general
license category and receipts for the trip, and don't assume a people-to-people itinerary
reads the same way at reentry that it did at booking.
Prevention · AIDS 2026, Rio, Aug 20
Open-label lenacapavir PrEP: zero HIV acquisitions in 4,206 women over a year
The open-label extension of PURPOSE 1, presented at AIDS 2026 in Rio and written up
Thursday, followed adolescent girls and women in Africa on twice-yearly injectable
lenacapavir. Of 4,417 participants eligible for the extension, 4,206 — 95.2% — chose to
start or continue on lenacapavir, and there were no HIV infections among anyone on
open-label drug. Beatriz Grinsztejn, president of the International AIDS Society, framed
the combined PURPOSE results as confirmation that twice-yearly dosing is safe, highly
effective, and — the part that had been the open question — actually adhered to when
people are given a free choice. The counterweight at the same meeting was access: the
rollout is getting decidedly mixed reviews.
(Medscape ·
Managed Healthcare Executive)
Why it matters to you: the inpatient consequence of long-acting injectables
is a medication-reconciliation problem, not an HIV problem. A patient on q6-month
lenacapavir has nothing in a pill organizer, nothing at the retail pharmacy, and nothing
their daughter can read off a bottle at 2 a.m. Ask "what pills do you take" and you will
miss it every time. The same blind spot already applies to long-acting antipsychotics,
q6-month denosumab, and the CGRP injectables your migraine patients are on.
Suggested action: worth checking whether your admission med-rec template
has a separate prompt for injections and infusions received elsewhere, with a date of last
dose. If it doesn't, that's a one-line build request with an outsized catch rate.
Update · DRC Ebola
Update: DRC's Ebola case-fatality rate has more than doubled since June — and this strain has no licensed vaccine
We flagged this outbreak passing 5,000 cases on Wednesday. The number that moved is the
one that matters clinically: case-fatality has climbed from roughly 20% in early June to
about 46% now, meaning nearly one in two confirmed cases is fatal. At 2,325 deaths the
outbreak has passed the 2,299 of the DRC's 2018–20 epidemic to become the deadliest in
the country's history — reached in three months rather than two years. The week of
August 3–9 was the worst yet, 579 cases and 304 deaths, with roughly 100 new cases every
24 hours as of August 12. Health workers account for at least 155 confirmed cases and 45
deaths. The underappreciated detail: the strain is Bundibugyo, which has caused
only three outbreaks in recorded history, and it has no targeted vaccine or therapeutic —
Ervebo, Inmazeb and Ebanga are all Zaire-strain products.
(CIDRAP ·
Al Jazeera ·
UN News)
Why it matters to you: the reflex answer when a febrile returning traveler
shows up — "there's a vaccine and there are antibodies for Ebola" — is wrong for this one.
The management is isolation, supportive care, and a phone call, and the difference between
those two mental models shows up in how fast the first call gets made. Southwest Florida
isn't a high-traffic corridor for DRC arrivals, but "low probability" and "no protocol" are
different things, and 3 a.m. is when the difference gets tested.
Suggested action: one question for infection prevention — does the VHF
pathway name a strain-specific step, or does it assume Zaire-strain countermeasures are
available? Same conversation you'd been meaning to have about the 21-day travel-history
prompt.
Section B — The Debate
One live argument, both sides, no verdict.
Is inflammation still a drug target in coronary disease after ZEUS?
Why it's live right now: ZEUS — more than 6,300 patients with established
atherosclerotic disease, chronic kidney disease and elevated hsCRP, the most enriched
population anyone has assembled to test the idea — reported a hazard ratio of 0.99 for
major adverse cardiac events. Ziltivekimab did exactly what it was designed to do to IL-6
and hsCRP and moved nothing that patients feel. Medscape reported Thursday that the
hypothesis's proponents are unmoved, which is what turned a trial result into an argument.
The case for — still a target
Mark Nidorf, cardiologist and LoDoCo2 investigator, in Medscape, Aug 20
The trial that failed tested one cytokine, not the concept. Colchicine — a cheap,
upstream, non-specific anti-inflammatory — has a six-trial meta-analysis across roughly
21,800 patients showing about a 25% reduction in the primary efficacy endpoint, and the
FDA approved low-dose colchicine for secondary prevention in established atherosclerotic
disease in 2023 on that evidence. What ZEUS actually undercuts is hsCRP as a treatment
target in an individual patient: CRP is a marker of risk, not a readout of the specific
inflammatory pathway driving a given person's plaque. Blocking IL-6 downstream of a
system with redundancy is a narrow test, and a null result there says less about
inflammation than the headline implies.
The case against — time to rethink the teaching
John Mandrola, cardiac electrophysiologist, in Medscape, Aug 12
This was the fair test and it failed. The population was selected for exactly the
mechanism in question, the drug engaged its target unambiguously, the biomarkers fell
as predicted — and myocardial infarction, stroke and death did not move. That is the
shape of a result that should update a belief rather than get explained around. The
broader lesson is about surrogates: a marker moving in the right direction is a
reasonable basis for a phase 2 program and no basis at all for treating patients. If
the response to a large, well-designed, appropriately enriched null trial is to
relocate the hypothesis one rung up the cascade, the hypothesis is getting harder to
falsify rather than better supported.
Where it might land: two more ziltivekimab outcomes trials read out in the
first half of 2027 — HERMES in heart failure and ARTEMIS after acute myocardial infarction —
which will settle whether the null result was about the drug's setting or about the idea.
That's the file, Marco. Go sleep. — Your morning desk